Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jul. 01, 2016
Cash flow from operating activities:
Net Income (loss)	$ 1,185	$ (19,598)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization expense	769	830
Equity-based compensation expense	491	824
Deferred income taxes	677	(247)
Deferred compensation	55	183
Goodwill impairment		21,544
Changes in assets and liabilities:
(Increase) decrease in accounts receivable	5,043	(2,319)
Increase in prepaid and other current assets	(223)	(1,082)
Increase in cash surrender value of life insurance	(762)	(891)
Decrease in accounts payable	(291)	(430)
Increase (decrease) in accrued compensation	(412)	237
Increase in advance billings on contracts	1,588	442
Decrease in other current liabilities	(562)	(168)
Increase (decrease) in income taxes payable	(611)	413
Increase in other long-term liabilities	69	67
Net cash provided by (used in) operating activities	7,016	(195)
Cash flow from investing activities:
Additions to property and equipment	(223)	(1,007)
Additions to capitalized software	(792)	(266)
Life insurance proceeds		394
Deferred compensation plan investments, net	(45)	(119)
Net cash used in investing activities	(1,060)	(998)
Cash flow from financing activities:
Proceeds from long-term debt	25,190	26,515
Payments on long-term debt	26,915	23,140
Proceeds from stock option plan exercises	727	229
Excess tax benefits from equity-based compensation		16
Taxes remitted for shares withheld from equity-based compensation transactions	(274)	(326)
Proceeds from Employee Stock Purchase Plan	79	113
Change in cash overdraft, net	28	(365)
Dividends paid		(1,884)
Purchase of stock for treasury	(3,343)
Net cash provided by (used in) financing activities	(4,508)	1,158
Effect of exchange rates on cash and cash equivalents	668	100
Net increase in cash and cash equivalents	2,116	65
Cash and cash equivalents at beginning of year	9,407	10,801
Cash and cash equivalents at end of quarter	$ 11,523	$ 10,866